Compare KYN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | TARS |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | N/A | 2020 |
| Metric | KYN | TARS |
|---|---|---|
| Price | $13.43 | $61.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $89.00 |
| AVG Volume (30 Days) | ★ 505.5K | 429.1K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | N/A | $30.19 |
| P/E Ratio | $19.01 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $11.31 | $38.51 |
| 52 Week High | $14.69 | $85.25 |
| Indicator | KYN | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 32.55 |
| Support Level | $12.07 | $61.24 |
| Resistance Level | $14.37 | $76.47 |
| Average True Range (ATR) | 0.27 | 3.04 |
| MACD | -0.04 | -1.07 |
| Stochastic Oscillator | 39.92 | 11.51 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.